Product Information
METRONIDAZOLE VAGINAL 0.75% GL is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.1406 per GM under NDC 68462018449. Its NADAC has been published 238 times since Mar 16, 2022.
FDA first approved this application on Jan 27, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5 mg/g
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462018449
Classification
Generic
Dosage Form
GEL
Route
VAGINAL
Effective Date
9/23/2026
Active Ingredients
METRONIDAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA215794FDA Approved
1/27/2022
TE Code
AB
On Market Since
1/27/2022
Pharmacological Classes
Price Statistics
The NADAC for METRONIDAZOLE VAGINAL 0.75% GL has been published 238 times since Mar 16, 2022, and over the history we have for it it has declined 76.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1406 per GM |
|---|---|
| All-time high | $0.6149 (Jun 15, 2022) |
| All-time low | $0.1405 (Jul 22, 2026) |
| 52-week high | $0.1847 |
| 52-week low | $0.1405 |
| Median price | $0.2900 |
| Average price | $0.3337 |
| Largest weekly change | -40.7% (Nov 20, 2024) |
| Weeks tracked | 238 |
| Tracking since | Mar 16, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Metronidazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nitroimidazole Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METRONIDAZOLE VAGINAL 0.75% GL?
The current National Average Drug Acquisition Cost (NADAC) for METRONIDAZOLE VAGINAL 0.75% GL, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.1406 per GM (NDC 68462018449), effective Sep 30, 2026.
How has the price of METRONIDAZOLE VAGINAL 0.75% GL changed over time?
Over the history we have for it, the NADAC for METRONIDAZOLE VAGINAL 0.75% GL has declined 76.8%. It has been tracked across 238 weekly CMS publications since Mar 16, 2022.
What are the highest and lowest recorded NADAC prices for METRONIDAZOLE VAGINAL 0.75% GL?
Since Mar 16, 2022, the NADAC for METRONIDAZOLE VAGINAL 0.75% GL has ranged from a low of $0.1405 (Jul 22, 2026) to a high of $0.6149 (Jun 15, 2022), with a median of $0.2900 per GM.
Are there cheaper alternatives to METRONIDAZOLE VAGINAL 0.75% GL?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as METRONIDAZOLE VAGINAL 0.75% GL in a comparable dosage form, but none are currently priced below it.
Who manufactures METRONIDAZOLE VAGINAL 0.75% GL?
METRONIDAZOLE VAGINAL 0.75% GL (NDC 68462018449) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.